Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Boston Scientific Corp | 49 |
| 2 | AbbVie Inc | 21 |
| 3 | Opna Bio SA | 20 |
| 4 | Otsuka Holdings Co Ltd | 7 |
| 5 | Amorepacific Corp | 6 |
| 6 | University of California | 5 |
| 7 | Symrise AG | 4 |
| 8 | Corning Inc | 3 |
| 9 | Hebrew University of Jerusalem | 3 |
| 10 | Agency for Science, Technology and Research | 2 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 139 |
| 2 | A61P | Therapeutic activity (drug indications) | 124 |
| 3 | C07K | Peptides | 60 |
| 4 | G01N | Investigating / analysing materials | 47 |
| 5 | C07D | Heterocyclic compounds | 44 |
| 6 | C12N | Microorganisms, enzymes | 27 |
| 7 | C07F | Organometallic compounds | 23 |
| 8 | C12Q | Measuring/testing involving enzymes | 15 |
| 9 | A61Q | Cosmetics, personal care | 14 |
| 10 | C07C | Acyclic and carbocyclic compounds | 13 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Application of sphingosylphosphorylcholine (SPC) in preparation of medicine for promoting endogenesis heart stem cells to be differentiated into heart lineage cells | 2015 | 5 | |
| Application of sphingosylphosphorylcholine in preparing anti-breast cancer drugs | 2016 | 1 | |
| Use of sphingosylphosphorylcholine antagonist for restoring the expression of antimicrobial peptides | 2009 | Amorepacific Corp | 1 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 9 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Martin C. Michel | University of Amsterdam | 9 |
| 2 | Hiroko Kishi | Yamaguchi University | 8 |
| 3 | Kid Törnquist | Minerva Foundation | 7 |
| 4 | Sarah Spiegel | Georgetown University Medical Center | 7 |
| 5 | Dagmar Meyer zu Heringdorf | Essen University Hospital | 7 |
| 6 | Jing Zhao | Shandong University | 7 |
| 7 | Károly Liliom | Hungarian Academy of Sciences | 6 |
| 8 | Genji Imokawa | Kao Corporation (Japan) | 6 |
| 9 | Fumikazu Okajima | Gunma University | 6 |
| 10 | Yoe‐Sik Bae | Sungkyunkwan University | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1 | 2000 | 290 | Protein Kinase Regulation and GTPase Signaling |
| Diagnostic tests for Niemann-Pick disease type C (NP-C): A critical review | 2016 | 146 | Lysosomal Storage Disorders Research |
| A novel membrane receptor with high affinity for lysosphingomyelin and sphingosine 1‐phosphate in atrial myocytes. | 1996 | 127 | Cellular transport and secretion |
| Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months | 2018 | 124 | Lysosomal Storage Disorders Research |
| Identification of key lipids critical for platelet activation by comprehensive analysis of the platelet lipidome | 2018 | 109 | Peroxisome Proliferator-Activated Receptors |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Sphingosyl-phosphocholine?
Which organizations hold the most patents related to Sphingosyl-phosphocholine?
What are the primary research topics associated with Sphingosyl-phosphocholine in the scientific literature?
What are the primary patent classification areas for Sphingosyl-phosphocholine inventions?
Who are the leading researchers publishing on Sphingosyl-phosphocholine?